Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 112-970 Burrard Street, Unit 1290 VANCOUVER BC V6Z 2R4 |
Tel: | N/A |
Website: | https://www.nervgen.com |
IR: | See website |
Key People | ||
William Joseph Radvak Executive Chairman of the Board, Co-Founder | Mike Kelly President, Chief Executive Officer | William J. Adams Chief Financial Officer, Company Secretary | Daniel D. Mikol Chief Medical Officer |
Business Overview |
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer's disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. The Company has two wholly owned subsidiaries, including NervGen US Inc. and NervGen Australia Pty Ltd. |
Financial Overview |
For the nine months ended 30 September 2023, NervGen Pharma Corp revenues was not reported. Net loss decreased 7% to C$13.8M. Lower net loss reflects Chemistry, manufacturing and controls decrease of 80% to C$859K (expense), Clinical and Regulatory decrease of 54% to C$1.1M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -C$0.30 to -C$0.23. |
Employees: | 10 as of Dec 31, 2022 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $126.18M as of Sep 30, 2023 |
Annual revenue (TTM): | $0.00M as of Sep 30, 2023 |
EBITDA (TTM): | -$19.54M as of Sep 30, 2023 |
Net annual income (TTM): | -$19.71M as of Sep 30, 2023 |
Free cash flow (TTM): | -$13.40M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 69,927,649 as of Apr 12, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |